TTA-P2 (3,5-Dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide) (compound (S)-5 in Fig. 3 of Shipe et al., 2008 (link)) (Merck & Co., Inc.) was made up as 10mM stock solution in dimethyl sulphoxide (DMSO), kept at −20°C until use and diluted for experiments so that the final concentration of DMSO was ≤0.03%. TTX was obtained from Latoxan, DL-APV from Fluka and CNQX from Tocris. All other chemicals were purchased from Sigma.
Concentration-response curves were generated from the percentage reduction in the peak T-type Ca2+ current amplitude evoked at −50mV. Quantitative comparison of action potential characteristics (threshold, amplitude, half-width) was performed on the first action potential of the spike trains evoked by 200pA depolarizing step from a holding potential of −60mV. Quantitative data in the text and figures are given as mean ± s.d.
Concentration-response curves were generated from the percentage reduction in the peak T-type Ca2+ current amplitude evoked at −50mV. Quantitative comparison of action potential characteristics (threshold, amplitude, half-width) was performed on the first action potential of the spike trains evoked by 200pA depolarizing step from a holding potential of −60mV. Quantitative data in the text and figures are given as mean ± s.d.
